How does gMG impact your patients?

Patient portrayal

The image above is a patient portrayal and partial depiction of the MG-ADL scale, which assesses the impact of gMG on daily functions of 8 signs or symptoms that are typically affected in gMG. Each function is scored from 0-3: 0 represents normal function and 3 represents the loss of ability to perform that function. A total score can range from 0 to 24.

gMG=generalized myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living.

FOR PATIENTS WITH gMG

The physical and psychological burdens can be severe and life-threatening^1-4

Up to 20% of patients experience a myasthenic crisis at least once in their lives, which can cause fatal respiratory failure^5,6

Symptoms are unpredictable, can make socializing difficult, and may increase feelings of anxiety and isolation^1,7,8

84% of patients are concerned about potential long-term side effects of immunosuppressive therapy⁹*

In addition to the burden of disease, research shows that patients may even refuse therapy or not be adherent to avoid negative side effects.^7,10†

*Data from an online survey collected from 283 self-identified MG patients and 45 MG physician experts. The goal of the survey was to better define patient and physician opinions about gMG, long-term immunosuppressant exposure, and dose reduction to inform the potential design of a randomized clinical trial.⁹

^†Data was collected from 41 patients with autoimmune MG using the Myasthenia Gravis Foundation of America classification system to analyze factors leading to unsatisfactory outcomes.¹¹
gMG=generalized myasthenia gravis; MG=myasthenia gravis.

I had to learn how to walk again . . . when you’re used to being independent, it feels almost embarrassing when people suddenly have to do everything for you.

—Real patient living with gMG

Could your patients benefit from the use of targeted treatments in conjunction with traditional therapies?^12‡

^‡Targeted therapies are treatments that target the underlying pathophysiological pathways of the disease.¹²

EXPLORE EVOLVING APPROACHES

Are your gMG patients struggling?

A survey showed that patients (n=28) still experienced the following effects of gMG, despite being on current commonly used treatments^13§:

93^%

reported muscle fatigability

93^%

reported eyelid drooping

89^%

reported an inability to participate in hobbies, sports, or social activities

82^%

reported difficulty breathing

^§Data collected from a qualitative, cross-sectional, non-interventional study in 28 people who reported receiving at least one treatment for gMG. Eligible participants were US residents, ≥18 years old, and comfortable reading and communicating in English. Study excluded people with only ocular disease to better understand the breadth of MG symptoms that affect all muscle groups.¹³
gMG=generalized myasthenia gravis; MG=myasthenia gravis.

I’m going to be a grandpa for the first time.
I want to hold my granddaughter.

—Real patient living with gMG

Learn more about evolving treatment approaches

Connect with us

Stay on top of the latest developments in gMG management by gaining access to additional resources as they're released.

References: 1. Twork S et al. Health Qual Life Outcomes. 2010;8:129. doi:10.1186/1477-7525-8-129 2. Boldingh MI et al. Health Qual Life Outcomes. 2015;13:115. doi:10.1186/s12955-015-0298-1 3. Eliasen A et al. J Neurol. 2018;265(6):1303-1309. doi:10.1007/s00415-018-8837-4 4. Chu HT et al. Front Psychiatry. 2019;10:481. doi:10.3389/fpsyt.2019.00481 5. Grob D et al. Muscle Nerve. 2008;37(2):141-149. doi:10.1002/mus.20950 6. Wendell LC, Levine JM. Neurohospitalist. 2011;1(1):16-22. doi:10.1177/1941875210382918 7. Howard JF Jr. Myasthenia Gravis: A Manual for the Health Care Provider. Myasthenia Gravis Foundation of America; 2009. 8. Suzuki Y et al. BMJ Open. 2011;1(2):e000313. doi:10.1136/bmjopen-2011-000313 9. Hehir MK et al. Muscle Nerve. 2020;61(6):767-772. doi:10.1002/mus.26850 10. Bacci ED et al. BMC Neurol. 2019;19(335). doi:10.1186/s12883-019-1573-2 11. Dunand M et al. J Neurol. 2010;257(3):338-343. doi:10.1007/s00415-009-5318-9 12. Sánchez-Tejerina et al. J Clin Med. 2022;11(21):6394. doi:10.3390/jcm11216394 13. Jackson K et al. Neurol Ther. 2023;12(1):107-128. doi:10.1007/s40120-022-00408-x